What is HC Wainwright’s Estimate for OVID FY2026 Earnings?

Ovid Therapeutics (NASDAQ:OVID) – Investment analysts at HC Wainwright upped their FY2026 earnings estimates for Ovid Therapeutics in a report released on Friday, September 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.36) per share for the year, up from their prior forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q4 2026 earnings at ($0.08) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.29) EPS.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.04. Ovid Therapeutics had a negative return on equity of 23.64% and a negative net margin of 240.11%.The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $0.02 million.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Friday, July 17th. B. Riley Financial reiterated a “buy” rating on shares of Ovid Therapeutics in a research note on Tuesday, July 21st. Oppenheimer boosted their price target on Ovid Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. Finally, Roth Capital reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Ovid Therapeutics in a research report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Ovid Therapeutics Price Performance

OVID stock opened at $2.74 on Tuesday. The company has a market cap of $535.12 million, a PE ratio of -8.84 and a beta of 0.24. The company has a current ratio of 12.39, a quick ratio of 12.39 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average price of $2.62 and a two-hundred day moving average price of $2.50. Ovid Therapeutics has a 12-month low of $1.12 and a 12-month high of $3.11.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OVID. Legal & General Group Plc acquired a new stake in shares of Ovid Therapeutics in the 2nd quarter valued at about $40,000. State of Wyoming bought a new stake in Ovid Therapeutics in the first quarter valued at about $49,000. E Fund Management Co. Ltd. acquired a new stake in Ovid Therapeutics during the second quarter valued at approximately $52,000. Focus Partners Advisor Solutions LLC acquired a new stake in Ovid Therapeutics during the second quarter valued at approximately $54,000. Finally, Stonepine Capital Management LLC bought a new position in Ovid Therapeutics during the 2nd quarter worth approximately $57,297. 72.24% of the stock is currently owned by institutional investors.

About Ovid Therapeutics

Ovid Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines for rare epileptic disorders and other diseases of the brain. The company’s research programs are designed to address significant unmet needs in patients with severe neurological conditions, including developmental and epileptic encephalopathies.

Ovid has developed a pipeline of investigational therapies targeting the underlying biology of epilepsy and related neurological disorders. Its programs have included soticlestat, an investigational treatment studied in rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome, as well as earlier-stage compounds aimed at modulating neurotransmission and reducing seizure activity.

Founded in 2014 and headquartered in New York, Ovid has advanced its programs through collaborations with larger pharmaceutical companies, including a collaboration with Takeda Pharmaceutical Company involving soticlestat.